Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ENDO PHARMACEUTICALS INC

Home Clinical Trial Sponsors and OrganizationsENDO PHARMACEUTICALS INC

ENDO PHARMACEUTICALS INC

70 High St, Rye, New York, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

9

6 active

Approvals

18

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

3

33.3%

Phase 1

1

11.1%

Trial Status Distribution

Active, not recruiting

6

66.7%

Unknown

2

22.2%

Withdrawn

1

11.1%

Clinical Trials

Trials sponsored by this organization (9)

A clinical trial to study the effects of EN3348 (MCC) as compared with Mitomycin C in the intravesical treatment of subjects with BCG recurrent or refractory non-muscle invasive bladder cancer

Jan 2012450 participants

ot applicable

Active, not recruiting

Dec 2011450 participants

EN3348 for treatment of Non-Muscule Invasive Bladder Cancer

Active, not recruiting

Dec 2011450 participants

EN3348 for treatment of Non-Muscule Invasive Bladder Cancer

Active, not recruiting

Dec 2011450 participants

ot applicable

Active, not recruiting

Nov 2011450 participants

Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant and/or Sandostatin LAR® depot in Patients with Acromegaly

Active, not recruiting

Nov 2008140 participants

A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of EN3285 for the Prevention or Delay to Onset of Severe Oral Mucositis in Subjects with Head and Neck Cancer Receiving Chemoradiotherapy - N/A

Active, not recruiting

Mar 2008180 participants

A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared with Mitomycin C in the Intravesical Treatment of Subjects with BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Page 1 of 2

Approvals

Approvals by Agency

FDA

Food and Drug Administration

18

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials9
Approvals18
News

Back to Organizations